Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis
Open Access
- 15 October 2019
- journal article
- research article
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 1-9
Abstract
Background: Cancer cachexia is a cancer-induced multifactorial debilitating syndrome directly accounting for 20% of cancer deaths without effective therapeutic approaches. It is extremely urgent to explore effective anti-cachexia drugs to ameliorate muscle and fat loss in cachexia patients. Methods: Lewis lung carcinoma bearing C57BL/6 mice were applied as the animal model to examine the therapeutic effect of Coix seed oil (CSO) on cancer cachexia. The food intake and body weight change were monitored every 3 days throughout the experiment. The IL-6 and TNF-α levels in serum were detected by ELISA assay. Several key proteins involved in muscle wasting and fat lipolysis were tested by Western blot to identify the potential mechanism of CSO. Results: Administration of CSO through gavage significantly prevented body weight loss and ameliorated systemic inflammation without affecting food intake and tumor size. The weight and histological morphology of gastrocnemius muscle and epididymal adipose tissue in CSO-treated mice were also improved. In mechanism, we found that CSO decreased the expression of MuRF1 and the ratio of phospho-p65 (Ser536) to p65 in muscle tissue. Meanwhile, cancer-induced activation of HSL and AMPK was also inhibited by CSO administration. Conclusion: Coix seed oil exerts an anti-cachexia pharmaceutical effect by counteracting muscle and adipose tissue loss most likely through regulating NF-κB-MuRF1 and AMPK-HSL pathway.Keywords
Funding Information
- national nature science (81572961)
This publication has 47 references indexed in Scilit:
- Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexiaThe American Journal of Clinical Nutrition, 2013
- The Relationships between Body Composition and the Systemic Inflammatory Response in Patients with Primary Operable Colorectal CancerPLOS ONE, 2012
- Desnutrin/ATGL Is Regulated by AMPK and Is Required for a Brown Adipose PhenotypeCell Metabolism, 2011
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Interleukin 6 as a Key Regulator of Muscle Mass during CachexiaExercise and Sport Sciences Reviews, 2010
- The role of cytokines in cancer cachexiaCurrent Opinion in Supportive & Palliative Care, 2009
- Is there a common mechanism linking muscle wasting in various disease types?Current Opinion in Supportive & Palliative Care, 2007
- Coix seed extract, A commonly used treatment for cancer in china, inhibits NFκB and protein kinase C signalingCancer Biology & Therapy, 2007
- Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissueAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—Correlations with food intake, metabolism, exercise capacity, and hormonesCancer, 2005